A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)

This publication has 8 references indexed in Scilit:

• Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
  Annals of Oncology, 2004
• Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer
  The Oncologist, 2003
• A Dose-Escalating Pilot Study of Sterically Stabilized, Pegylated Liposomal Doxorubicin (Lipo-Dox®) in Patients with Metastatic Breast Cancer
  Cancer Investigation, 2003
• EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer
  Annals of Oncology, 2002
• Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
  Journal of Clinical Oncology, 2001
• Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
  Annals of Oncology, 2000
• High Intratumoral Accumulation of Stealth Liposomal Doxorubicin in Sarcomas: Rationale for Combination with Radiotherapy
  Acta Oncologica, 2000
• Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
  Journal of Clinical Oncology, 1997